Wyeth Effexor Promotions Cited For Superiority Claims In FDA Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The ad division letter follows an Office of Personnel Management Inspector General investigation into Wyeth's Effexor marketing practices. FDA asserts that Wyeth's claims of superiority to SSRIs are unsubstantiated.
You may also be interested in...
Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.
Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts
Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.
GSK Paxil CR Ad Medicalizes "Ordinary" Anxiety, FDA Says
TV ads "broaden" use of the antidepressant beyond social anxiety disorder and into attributes that "do not generally require psychopharmacological treatment," FDA ad division letter says. Risk information is minimized by distractions and failure to note contraindications, FDA says.